Eltrombopag
Composition
The formulation contains Eltrombopag 25 mg/50 mg with microcrystalline cellulose, lactose monohydrate, magnesium stearate, and croscarmellose sodium as the active ingredient.
Indications
Indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and chronic hepatitis C-associated thrombocytopenia.
Side effects
Common side effects include headache, nausea, liver enzyme abnormalities, and increased risk of thrombosis.
Precautions
Monitor liver function tests, blood counts, and signs of thromboembolism; use with caution in patients with hepatic impairment or a history of thromboembolic events.
Contraindications
Contraindicated in patients with a hypersensitivity to Eltrombopag or a history of thromboembolism.
Dosage and administration
The recommended dosage varies depending on the patient's weight and platelet count, usually starting at 50 mg orally once daily.
Countries
Available globally.
Available Forms
Tablets